

Deemed-to-be-University B. S. Devashi Marg (Govandi Station Road) Deonar, Mumbai, Maharashtra 400088 https://www.iipsindia.ac.in/

IIPS-IRB Application Form

Serial No of IIPS-IRB Management Office:

Application form for the review of the proposal								
<i>b</i>)	To be filled by the Prin Please tick mark the ap Attach a separate shee	ppropriate one, mark N	: A if not applicable; and					
Title of the Propos	Fitle of the Proposal :							
Name of the Applicant :								
Name of the Prince	ipal Investigator :	•••••	•••••					
Designation	:	•••••	• • • • • • • • • • • • • • • • • • • •	•••••				
Department	:	•••••	• • • • • • • • • • • • • • • • • • • •	•••••				
Date of submission	ı :	•••••	•••••	•••••				
Type of review Exemption from Review Expedited Review Full Committee Review Status of Review: New Revised								
	SECTION A: AD	MINISTRATIVE	INFORMATION					
Project Investigators	Name, Qualifications and Designation	Department and Organization Address and contact details	Roles and responsibilities	Signature				
PI:								
Co-PI:								
			PIs and Co-PIs) in previous 5 years).	volved in the				

Funding Details

Project Duration:			
Total Budget:			
1 viii Buugeii			
Share of the sponsor/s in the total b	udge	t:	
Sponsor Information:			
1. Indian a) Government	i. Ce	ntral 🔲 ii. Sta	te 🔲 iii. Institutional 🗖
b) Private 🔲 i. Indu	stry [ii. Development age	ncy 🔲 iii. Self-sponsored 🔲
2. International Government		Private	UN agencies Other
3. Industry National		Multinational	
3. maistry Patronal			
Specify the funding agency:			
Contact Address of Sponsor:			
	W1100 5 555	RCH RELATED INF	
l -	•		h question aim(s) & objectives,
			monitoring and auditing, outcome
measures, statistical analysis a	ind im	iplication of the researc	ch findings (maximum 500 words):
2. Objectives of the study			
2. Objectives of the study			
Type of Study: (Tick \sqrt{X})			
Socio-Behavioural Science		Retrospective	Cross sectional
Clinical Single center		Prospective	Longitudinal/cohort
Clinical Multi- centric		Quantitative	Case control
Epidemiological and Public health		Qualitative	Systematic review
Basic science		Mixed method	Baseline
Biological sample			Endline
			Formative \Box

3. Clinical Trials: Drug /Vaccines/Device/Herbal Remedies:		
i. Does the study involve use of: Drug Devices	Vaccines -	_
Drug Devices	v accines	1
Indian Systems of Medicine/ Any other Alternate System of Medicine	NA 🗆	1
ii. Is it approved and marketed		
In India 🔲 UK & Europe 🔲	USA 🗖	
Other countries, specify		
iii. Does it involve a change in use, dosage, route of	Yes	No
administration?		
If yes, whether DCGI's /Any other Regulatory authority's	Yes	No
Permission is obtained?		
If yes, Date of permission:		
if yes, Date of permission.		
iv. Is it an Investigational New Drug?	Yes	No
If yes, IND No:		
a). Investigator's Brochure submitted	Yes	No
b). In vitro studies data	Yes	No
c). Preclinical Studies done	No	
d). Clinical Study is: Phase I Phase II Phase III	Phase IV	
4. Are you aware if this study/similar study is being done else	where?	Yes No
If Was approved a data its		
If Yes, provide details		
SECTION C: PARTICIPANT RELATED INFO	RMATION	
5. Subject selection:		
i. Number of Subjects: Sampling design and Sample Size	;	
The rationale for the selection of sample six in 100 words. In case	of qualitative	study describe
the number and type of respondents.		
ii. Duration of fieldwork:		
iii. Will subjects from both sexes be recruited		Yes No

Annexure 1: IIPS-IRB: Application Form

iv.	Please provide the in of respondents	clusion and excl	usion criteria	of the selection	on		
V.	Type of subjects	Volunteers		Patients			
vi.	Vulnerable subjects				Yes		No 🗖
	If Vulnerable subjec	ts, Tick the appro	opriate boxes				_
	Pregnant Women Fetus Terminally ill Economically & Soc	Illiterate Seriously i		Elderly Handicappe Mentally ch Any other	allenge		
iv.	Special group subject	cts			Yes		No 🗖
	If yes in special subj	ect group, tick th	e appropriate	boxes			
	Captives Students Any Other	Institutionalize Nurses/Depen	_		oloyees ed For		
6. Privacy ar	nd confidentiality Study involves -	Indirect	lentifiers Identifiers/co				
ii.	Confidential handling	of data by staff		Yes		No	NA
	logical/ hazardous ma of fetal tissue or abort			Yes		No	NA
	of organs or body flui			Yes		No	NA
iii. Use	of recombinant/gene t	herapy		Yes		No	NA
	epartment of Biotechno products been obtained		roval for	Yes		No	NA
iv. Use	of pre-existing/stored/ ples	left over		Yes		No	NA
v. Coll	ection for banking/fut arch	ure		Yes		No	NA
vi. Use	of ionizing radiation/r	adioisotopes		Yes		No	NA

If yes, has Bhabha Atomic Research Centre (BARC)	Yes	No	NA
approval for Radioactive Isotopes been obtained?			
vii. Use of Infectious/biohazardous specimens	Yes	No	NA
viii. Proper disposal of material	Yes	No	NA
viii. Troper disposar of material	1 65	INO	INA
' XX'11 1 11 (1 C (1 (1 (1 (1 (1 (1 (1	37) I	NIA
ix. Will any sample collected from the patients be sent	Yes	No	NA
abroad?			
If Yes, justify with details of collaborators:			
a) Is the proposal being submitted for clearance from Health M	linietry's	Yes	No
		103	110
Screening Committee (HMSC) for International collaboration	OII (
b) Sample will be sent abroad because (Tick appropriate box):			
Facility not available in India			
Facility in India inaccessible			
Facility available but not being accessed			
•			
If so, reasons			
Informed Consent			
Are you seeking waiver of consent? If yes, please specify reason	s and skip to item i	no. 8	
	1		
Yes No D			
T			
Type of consent planned		. 1	
*Written/Signed	☐ Audio-	visual	
In case of a minor children:			
Verbal assent from of minor (7-12 yrs.) along Wri	tten assent from of	minor (13	3-18
) along with parent		
with parchar consent	along with parent	ai consciii	ш
List of languages in which translation is done			
Details of number of consent or/assent to be obtained in the s	tudv		
beams of number of consent of assent to be obtained in the s	iuuj		

i. Tick the included elements in the	Consent form		
Understandable language Statement that study involves resear Sponsor of study Purpose and procedures Risks & Discomforts Benefits Compensation for participation Compensation for study related injust Translated in local language *If written consent is not obtain	Contact information Statement that consent is voluntary Right to withdraw Consent for future use of biological r Benefits if any on future commercials e.g. genetic basis for drug development	ization	
ii. Who will obtain consent?	PI/Co-PI Nurse/Counsellor		
n. who will obtain consent :	Research staff Any other		
8. Payment/Compensation			_
Will you provide any for	n of payment/compensation to the participar	nts Yes	No
as a result of their partici		165	
-	of the payment/compensation		1
9. Will any advertising be done for (posters, flyers, brochure, website		Yes	No
10. Risks & Benefits:			
i. Is there physical / social / p If Yes, Minimal or no risk More than minimum risk High risk	sychological risk / discomfort?	Yes	No
In case if risks are involved, mention	the risks and risk addressing mechanism:		
Risk			
Risk addressal mechanism			

ii. Is there a potetial benefi	t ?					
a) to the subject		No benefit	Direct benefit	Indi	rect ben	efit 🔲
b) to the society		No benefit 🗖	Direct benefit	Indi	rect ben	efit 🗖
c) for improvement in knowledge Mention the benefits:		No benefit 🗖	Direct benefit	Indi	rect ben	efit 🗖
Miention the denemits:						
Storage and Confidentiality						
a) Identifying Information: Study	Invol	ves samples/data.	If Yes, Specify			
Yes No No NA						
Anonymous/unidentified A	nonyı	mized: reversibly	coded 🗖 Irreversib	ly cod	ed	
Identifiable						
If identifiers must be retained, wh	nat ado	litional precaution	ns will be taken to ensu	ire tha	it access	s is
limited / data is safeguarded? (e.g	g. data	stored in a cabine	et, password protected	comp	uter etc.)
b) Who will be maintaining the d	ata pe	rtaining to the stu	dy?			
c) Where will the data be analysed and by whom?						
d) For how long will the data be stored?						
e) Do you propose to use stored samples/data in future studies? Yes No Maybe						
If yes, explain how you might use	e store	d material/data in	the future?			
	CECT	PION D. OTHE				
11. Data Monitoring	SEC	TION D: OTHE	K 185UES		Yes	No
i. Is there a data & safe	ety mo	nitoring committe	ee/ Board (DSMB)?		103	110
iii. Is there a plan for report	ing of	adverse events?			Yes	No
If Yes, reporting is done to	:					
			DSMB			
iii. Is there a plan for inter					Yes	No
vi. Are there plans for stor	age an	d maintenance of	all trial		Yes	No

database?			
If Yes, for how long?			
12. Is there compensation for participation?	Yes	No	
If Yes, Monetary In kind			
Specify amount and type:			
13. Is there compensation for injury?		Yes	No
If Yes, by Sponsor □ by Investigator □ by Insurance □ by any other company □			
14. Do you have conflict of interest?		Yes	No
(financial/nonfinancial)			
If Yes, specify:			
SECTION E: CHECK LIST AND DECLARATION	N		
Cover letter	Yes	No	NA
Compactification of the control IDD France (4 and a)	X 7	NT.	NT A
Copy of filled-in and duly signed IRB Form (4 copies)	Yes	No	NA
Project proposal – 4 Copies	Yes	No	NA
Short bio of the invigilators	Yes	No	NA
Curriculum Vitae of Investigators in prescribed format	No	NA	
In case of collaborative research, attach the MOU with the collaborating organization	No	NA	
Format of review type	Yes	No	NA
Participant information sheet-cum-Informed Consent form, (if multiple respondents, consent should be taken from each respondent)	Yes	No	NA
Informed Assent form (If applicable)	Yes	No	NA
Investigator self-declaration form	Yes	No	NA
Questionnaire and/or Copy of clinical trial protocol and/or interview guidelines	Yes	No	NA
Investigator's brochure for recruiting subjects	Yes	No	NA

Annexure 1: IIPS-IRB: Application Form

Copy of advertisements/Information brochures	Yes	No	NA
Institutional Animal Ethics Committee clearance	Yes	No	NA
Any other specify	Yes	No	NA
CPCSEA clearance, if any	Yes	No	NA
HMSC/DCGI/DBT/BARC clearance if obtained	Yes	No	NA
Survey Protocol on COVID-related Measures	Yes	No	NA
Any other information:			
Any other information:			

Date:	Principal Investigator
Place:	



Deemed-to-be-University
B. S. Devashi Marg (Govandi Station Road)
Deonar, Mumbai, Maharashtra 400088
https://www.iipsindia.ac.in/

IIPS-IRB

CV Format for Investigators

Format Curriculum Vitae for Investigators

Name:	
Present affiliation (Job title, department, and org	ganization):
Address (Full work address):	
Telephone number:	Email address:
Qualifications:	
Previous and other affiliations (Include previous	s affiliations in the last 5 years)
Projects undertaken in the last five years:	
Relevant research training/ experience in the a	rea:
Attended Ethical Training (if any):	
Relevant Publications (Give references to all rel	evant publications in the last five years):
Signature	Date: Click here to enter a date.



Deemed-to-be-University
B. S. Devashi Marg (Govandi Station Road)
Deonar, Mumbai, Maharashtra 400088
https://www.iipsindia.ac.in/

IIPS-IRB

Expedited Review

Title of study:	
Principal Investigator (Name, Designation, and Affiliation):	
1. Choose reasons why expedited review from EC is requested ¹ ?	
i. Involve non-identifiable specimen and human tissue from sources like blood banks, tissue banks and left-over clinical samples	
ii. Involve clinical documentation materials that are non-identifiable (data, documents, records).	
iii. Modification or amendment to approved protocol (administrative changes/correction of typographical errors and change in researcher(s))	
iv. Revised proposals previously approved through expedited review, full review or continuing review of approved proposals	
v. Minor deviations from originally approved research causing no risk or minimal risk	
vi. Progress/annual reports where there is no additional risk, for example activity limited to data analysis. Expedited review of SAEs/unexpected AEs will be conducted by SAE subcommittee.	
vii. For multicentre research where a designated EC has approved the proposal, a participating EC may review participating centre specific information and modification in the study proposal through full committee meeting/ expedited review depending on the importance of local consent related issues involved specific to the centre.	
viii. Research during emergencies and disasters (See Section 12 of ICMR Ethical Guidelines, 2017).	
ix. Any other (please specify)	
2. Is waiver of consent being requested? Yes	No 🔲
	No 🔲
If Yes give details (attach a separate sheet):	

Signature of PI:

Comments of Project Cell:

Signature of Convener:

¹Refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 51 Table 4.2 2For details, refer to application for initial review, Section-C, 5(b)

^{*}In case this is first submission, leave it blank



Deemed-to-be-University
B. S. Devashi Marg (Govandi Station Road)
Deonar, Mumbai, Maharashtra 400088
https://www.iipsindia.ac.in/

IIPS-IRB

Exemption from Review

Title of study:	
Principal Investigator (Name, Designation, and Affiliation):	
1. Choose reasons why exemption from ethics review is requested ^{1,2} ?	
i. Research on data in the public domain/ systematic reviews or meta-analyses	
ii. Observation of public behaviour/ information recorded without linked identifiers and disclosure	
would not harm the interests of the observed person	
iii. Quality control and quality assurance audits in the institution	
iv. Comparison among instructional techniques, curricula, or classroom management methods	
v. Consumer acceptance studies related to taste and food quality	
vi. Public health programmes by government agencies	
vii. Any other (please specify in 100 words)	

Signature of PI:

Comments of Project Cell:

Signature of Convener:

1Select the category that applies best to your study and justify why you feel it should be exempted from review. For a detailed understanding of the type of studies that are exempt from review, refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 51 Table 4.2

²Such as programme evaluation where the sole purpose of the exercise is refinement and improvement of the programme or monitoring (where there are no individual identifiers)

^{*}In case this is first submission, leave it blank

General Guidelines

[Title of your Institute]

Informed Assent Form (Respondents under age 18)

[Informed assent form should be on the Institute's letterhead]

Assent refers to agreeing or approving after thoughtful consideration an idea or suggestion to participate in research by a young person below the age of 18 years, who is old enough to understand the implications of any proposed research but not legally eligible to give consent. The assent has to be corroborated with the informed consent of the parent.

Obtaining Informed Assent from Children or Minors Parents, legal guardians, or a legally authorized official must sign consent forms permitting children or minors to participate in research projects. In addition, children and minors are required to sign an Assent Form.

The content of an assent form for children participating in research should be tailored to their age and understanding. It should be written in simple, clear language that aligns with their cognitive, social, and emotional development. Here's a breakdown of key points to include:

Key components to include are:

1. Explanation of the Study (Benefit & Purpose):

a. Briefly explain the research project and how it might benefit children like them in a child-friendly way. Mention the activities involved in the study, including any potential discomfort the child might experience.

2. Study Procedures and Potential Discomfort:

- **a.** Describe the activities involved in the study, using simple language and avoiding medical jargon.
- b. Mention any potential discomfort the child might experience and assure them it will be minimized.

3. Right to Ask Ouestions and Contact Information:

- a. Emphasize that the child can ask questions about the research at any time.
- b. Provide contact information for a person the child can reach with questions or concerns (e.g., researcher, parent liaison).

4. Voluntary Participation and Confidentiality:

- a. Clearly state that the child's participation is voluntary and they can refuse to participate or withdraw at any point without impacting their treatment or care.
- b. Assure them that refusing will not affect their treatment or care at the center.

5. Consent and Contact Information:

a. Provide contact information for a person the child can reach with questions or concerns.

Sample:

[Project Title:]

My name is [Your Name], and I'm here to talk to you about a study we're doing about [Project Title and Brief description of the study in child-friendly language].

Your parent(s)/guardian(s) have already given their permission for you to participate, but it's completely up to you if you want to be part of it [explain the voluntary nature of participation and right not to participate and withdraw]

You may feel some inconvenience because of the time and effort to be a participant. You may also find some questions that we ask to be upsetting or may feel embarrassed to answer them [mention any potential discomfort in a gentle way].

You do not have to respond to any question that makes you uncomfortable and you may stop the interview at any time and nothing will happen. There are no direct benefits to participating in the study, although you will help us understand what children like you want or need.

Your participation is entirely voluntary and you can stop the interview at any point of time even after having agreed to participate. If you decide not to participate it will not affect any benefits to which you are entitled. I want to assure you that the information you provide during the study will be kept private and confidential.

If you have any question, please feel free to ask them to me. Or you can also contact the Project PI on the following address. [Address questions of the child regarding the survey if any]

Principal Investigator: [Name, Affiliation, Office, Mobile, Email Address]

[Principal Investigator and Contact Information]

Do you agree to participate in this survey? [Verification of child's consent]

Tick the answer:

- 1. Consent given along with signature/thumb impression
- 2. Consent given but without signature/thumb impression
- 3. Consent Refused

[Interviewer's Declaration]

I confirm that the individual has given consent freely. I have taken consent from parents (assent from in case of minor) before the interview

Interviewer's Name and signature:	Date:	/	/	

Guidelines for the Informed Consent

An informed consent form must include the following:

- 1. Obtaining an Informed Consent is not simply obtaining a signature on a prescribed format rather, it is a process of sharing information and addressing questions and concerns of the participant.
- 2. It is based on the principle that competent individuals are entitled to choose freely whether or not to participate or continue to participate in the research.
- 3. Participants must then give their consent to participate on an informed consent form developed specifically for the research project.
- 4. There are very few research situations where a participant's signature on informed consent is not required. However, permission from IRB is always required for waving off of the signature.
- 5. The informed consent form should be submitted in English as well as in local language(s).
- 6. The goal and objective of research in simple jargon-free language. The language should not only be scientifically accurate and simple, but should also be sensitive to the social and cultural context of the participant.
- 7. Informed consent is a continuous process involving three main components:
 - a) providing relevant information to potential participants,
 - b) ensuring the competence of the individual, ensuring the information is easily comprehended by the participants, and
 - c) ensuring voluntariness

IIPS-IRB: Informed Consent Form

Part - A

International Institute for Population Sciences



Deemed-to-be-University
B. S. Devashi Marg (Govandi Station Road)
Deonar, Mumbai, Maharashtra 400088
https://www.iipsindia.ac.in/

IIPS-IRB

Informed Consent Form

[Project Title:]

1. [Introduction]

GreetingsSelf-introduction Statement mentioning that it is research

2. [Purpose of Your Study]

- Clear the research objectives and outcome of the study
- [Respondent's Role]-Explain the procedure to participate in the interview/survey. Explanation of all the research tools employed. Reasons or methods for inclusion/exclusion of the particular group or individual(s) in the community or in any other settings, for participation in the survey should be briefed.
- Detailed description of the methodology
- [Time]-Approx. estimated time to complete the survey
 - *The interview will take approximatelyminutes to complete.*

3. [Risks or Benefits]-

- Risks: [Describe any potential risks/ discomfort/ inconvenience associated with participation.]
 - You may feel some inconvenience because of the time and effort to be a participant. In case of sensitive surveys, including questions on You may also find some questions that we ask to be upsetting or may feel embarrassed to answer them. You do not have to respond to any question that makes you uncomfortable and you may stop the interview at any time and nothing will happen.
- Benefits: [Explain any potential benefits to participants or community.]
 - There are no direct benefits to participating in the study, although you will help us understand what children like you want or need

4. [Privacy/Confidentiality/Data Security]

• It is necessary to maintain the privacy and confidentiality of participants at all stages.

- The extent of privacy, anonymity, and confidentiality that will be provided to participants
 - The information shared by you will be kept confidential and will not be shared with anyone, and will be used only for research purposes.
- [Data Sharing- Data collected will be completely anonymized / partially anonymized]
- The data will only be used for research and planning purposes without any personal identification.

Suppose in the case of Indirect Identifiers, you may give:

- All the information you provide will be strictly confidential, and your name will not appear on the questionnaire. Instead, your questionnaire will contain an identification number that is known only by the principal investigator of this study.
- No one including your family members, friends, or other members of the community will ever know that you have not participated in the survey and no one will know what answers you gave since we do not collect information about your name etc.
- [Information on any follow-ups of survey if any]
 - The survey team may also re-contact you if it is necessary to complete the information in the survey.
- [Voluntary nature of participation and Right not to participate and withdraw]
 - Your participation is voluntary. You may refilse to participate or may discontinue your participation at any time during the survey. You can also choose not to answer any questions.
- [Importance of the response/survey and future use of the information]
 - Your responses are very important to us and the community, as these answers will represent many other people. This is an important study and I hope you will participate fully.

5. [Contact information]

We will leave the necessary contact information with you. If you have any questions or concerns about this study, please contact on the address given below.

6. [Address questions of the Respondent regarding the survey if any]

- Do you have any questions?
 - Should you have any question about the survey please feel free to ask me or contact the concerned authority.

[Principal Investigator and Contact Information]

Principal Investigator: [Name, Affiliation, Office, Mobile, Email Address]

7.	[Consent]	Respondent's	willingness	to participate	in	the study

• Do you agree to participate in this survey?

[Verification of consent]

Tick the answer:

- 1. Consent is given along with signature/ thumb impression
- 2. Consent is given but without signature/thumb impression
- 3. Consent Refused

[Interviewer's Declaration]

I have informed the respondent about t	he project, risk and	l benefit and also c	onfidentially 1	risk taken
consent from the respondent before the	e interview.			

Interviewer's Name and signature:]	Date:	/	/	/
$\boldsymbol{\mathcal{C}}$		-			

IIPS-IRB: Informed Consent Form

Part - B

International Institute for Population Sciences



Deemed-to-be-University
B. S. Devashi Marg (Govandi Station Road)
Deonar, Mumbai, Maharashtra 400088
https://www.iipsindia.ac.in/

IIPS-IRB

Informed Consent Form

Informed Consent Form

I confirm that:

- I have had the opportunity to ask questions, and all my queries have been answered to my satisfaction.
- I understand that my participation in this research study is entirely voluntary, and I have the right to withdraw from the study at any point without giving any reason and without affecting my current or future medical treatment or relationship with the researchers.
- I understand the risk & benefits of participating in this study.
- I understand that refusing to participate or withdrawing will not result in any penalty or loss of benefits to which I am entitled.
- I understand that my personal information and data collected during this study will be kept confidential. Only the researchers involved in the study, the sponsoring agencies, regulatory authorities, and IRB may access my records if necessary, for monitoring and auditing the study in line with the ethical guidelines.
- I understand that the data will be anonymized for any future use, and my identity will not be revealed in any reports or publications that come out of this research.

By signing this consent form, I willingly agree to participate in this study. I understand that I c	an
withdraw at any time without giving a reason and without any loss of benefit.	

.....

For participants with limited or non-readers:

I, [Witness Name], have witnessed the consent procedure of the study participant. The participant had the opportunity to ask questions, and I confirm that the individual has given consent freely and voluntarily after understanding the study's purpose and their role in it.
Name of the Participant/Guardian:
Signature/Thumb Impression of the Participant/Guardian:
Witness (for non-readers):
(Signature and Name)
Name of the Person Administering the Consent:
Signature of the Person Administering the Consent:
Date:
•••••••••••••••••••••••••••••••••••••••
Principal Investigator (PI):
Contact Information: [Insert PI's Contact Details]
Co-Principal Investigator (Co-Pl):
Contact Information: [Insert Co-PI's Contact Details]
Note: All parties signing the consent form must date their own signature

Part-A

International Institute for Population Sciences



Deemed-to-be-University
B. S. Devashi Marg (Govandi Station Road)
Deonar, Mumbai, Maharashtra 400088
https://www.iipsindia.ac.in/

IIPS-IRB

Self-Declaration Form

DECLARATION BY THE PRINCIPAL INVESTIGATOR

Stud	y Title:
I h	ereby declare that:
1.	Voluntary written consent of the human subject will be obtained.
2.	In case of children and mentally handicapped subjects-voluntary written informed consent
	of the parents/guardians will be obtained.
3.	The probable risk involved in the project will be explained in full details to the subjects/
	parents/ guardians.
4.	Subjects/ parents/ guardians will be at liberty to opt out of the project at any time.
5.	I will terminate the study at any stage, if have probable cause to believe, in the exercise of
	the good faith, skill and careful judgement required for me that continuation of the
	experiment is likely to result in injury, disability of death to the experimental subject.
Date	•
	(Signature of Principal Investigator)
	Department

Part-B

International Institute for Population Sciences



Deemed-to-be-University
B. S. Devashi Marg (Govandi Station Road)
Deonar, Mumbai, Maharashtra 400088
https://www.iipsindia.ac.in/

IIPS-IRB

Self-Declaration Form

(DECLARATION BY THE PRINCIPAL INVESTIGATOR / DIRECTOR)

Study Title:			
1) Is the Department/ University ready to undertake the responsibility of the human subjects in case of injury? If yes, then will it include	Yes	No	NA
Transportation charges	Yes	No	NA
 Hospitalization 	Yes	No	NA
2) Do you think that the study is so designed that they would yield meaningful results that could not be obtained by the other method?	Yes	No	NA
3) Do you think that the animal experiments carried put support the need for clinical experimentation?	Yes	No	NA
4) Do you think that the study would be conducted in a manner to avoid all unnecessary physical and mental suffering and injury?	Yes	No	NA
5) Do you think the experiments have been planned in a manner so that the degree of risk to be taken would never exceed that determined by the humanitarian importance of the problem to be solved by the experiment?	Yes	No	NA
6) Do you think that proper preparations would be made and adequate facilities provided to protect the study subject against even remote possibilities of injury, disability or death?	Yes	No	NA
7) Do you think that safeguards have been taken to see that the research would be conducted only by scientifically qualified persons who possess the requisite competence, experience and qualities to carry out the research?	Yes	No	NA

Date:

(Signature of Principal Investigator)

(Signature of Director)

IIPS Letter Head

No. /
Date:

Institutional Review Board (IRB00013212)

Chairperson Prof. D.P Singh Project title: TISS Name & Address of Institution: International Institute for Population Sciences, Convener Deonar, Mumbai - 400088 Prof. Aparajita Chattopadhyay, Principal Investigator: Name of Co-PIs: **IIPS** Name: Contact Number: **Members** Email ID: Prof. Gajanan Velhal, Collaborators' Name: Sponsor: B K L Walawalkar Address: Rural Medical Contact. No.: College, Ratnagiri Email: **Review Status:** Prof. Archana K. Roy, IIPS The following item $\lceil \sqrt{\rceil}$ have been received and reviewed in connection with the above study to be conducted by the above investigator. [.....] Participant Information Sheet Dr. Lalita [.....] Study Protocol / Synopsis Savardekar, **ICMR-NIRRH** [.....] Summary of Change Document (in case of a revision) [.....] Informed Consent Form [.....] Investigators' CVs Prof. Vaishali Kolhe, TISS And have been $\lceil \sqrt{\rceil}$ [....] Approved Ms. Sushmita Das, Society for Nutrition, Comments (if any): Education Date of Approval: & Health Action Please note: (SNEHA) - Inform IRB immediately in case of any adverse events and serious adverse Dr. Vinod B Joshi, - Inform IRB in case of any change of study procedure, site and investigator. Advocate for Govt of - Members of IRB have right to monitor the pretesting procedure with prior India - Law intimation. - Members of IRB have right to monitor the field procedure with prior intimation. Member **Secretary** Dr. (Mrs.) Manjiri

Chairperson

IRB Committee

M. Rane, IIPS

Convener

IRB Committee